LTRN separates AI unit to capitalize on a projected $10 billion market opportunity by 2030-2031.
Lantern Pharma has spun off Open Medicine AI as an independent company, retaining commercial licenses and agreements to advance its AI data models. The move targets a $10 billion market outlook by 2030-2031, according to management during the Q2 2026 earnings call.
The separation aims to accelerate development and commercialization of AI-driven drug discovery tools. Lantern previously highlighted AI as a key growth driver, though specific financial details of the spin-off were not disclosed.
No immediate market reaction was reported following the announcement.